These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Review of viral load and combination therapy data from 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Author: Bray JM.
    Journal: STEP Perspect; 1995; 7(3):10-1. PubMed ID: 11362980.
    Abstract:
    Research on HIV viral loads and combination therapy was presented at the 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Research has shown that ten billion HIV particles are produced daily in an infected individual's body. The HIV particles live freely for about eight hours before infecting CD4 cells, which live for 2.2 days before dying. The virus replicates in about 1.2 days. This is a faster rate of replication than previously thought. The specific proteins needed for cytotoxic lymphocytes to recognize an infected CD4 cell may not be available with so many viral mutations constantly occurring. Combination therapies are believed to decrease drug-resistant strains of HIV by reducing replication and by increasing the number of mutation sites needed for new HIV virions to be produced. A research study, ACTG 175, compared four treatments: zidovudine (ZDV) alone, ddI alone, ZDV plus ddI, and ZDV plus ddC. The results showed that ZDV alone was the least effective treatment, even when it was the initial treatment. ZDV plus ddI was the most effective for people who had previously taken ZDV, and ZDV plus ddC was the most effective for ZDV-naive participants. Delta, a European and Australian trial, reported similar results.
    [Abstract] [Full Text] [Related] [New Search]